Department of Pharmacology, Wakayama Medical University, Japan.
Eur J Pain. 2012 Oct;16(9):1271-80. doi: 10.1002/j.1532-2149.2012.00146.x. Epub 2012 Apr 24.
Neuropathic pain is caused by neural damage or dysfunction and neuropathic pain-related symptoms are resistant to conventional analgesics. Neuroinflammation due to the cytokine-chemokine network may play a pivotal role in neuropathic pain. We demonstrate that macrophage inflammatory protein-1β (MIP-1β) participates in neuropathic pain.
Mice received partial sciatic nerve ligation (PSL), and tactile allodynia and thermal hyperalgesia were assessed by von Frey test and Hargreaves test, respectively. Agents were administered into the region surrounding the sciatic nerve (SCN).
Using reverse transcription polymerase chain reaction, the mRNA expressions of MIP-1β and its receptor (CC-chemokine receptor 5; CCR5) in the injured SCN were up-regulated after PSL. MIP-1β immunoreactivity was localized in macrophages and Schwann cells and increased in the injured SCN on day 1. PSL-induced tactile allodynia on days 4 to 7 was prevented by the administration of MIP-1β neutralizing antibody (anti-MIP-1β; on days 0, 3 and 6). PSL-induced up-regulations of inflammatory cytokine-chemokine mRNAs in the injured SCN were suppressed with anti-MIP-1β treatment on day 7. Administration of CCR5 antagonist, D-ala-peptide T-amide (on days 0, 3 and 6) prevented tactile allodynia and thermal hyperalgesia on days 4 to 14. Single administration of recombinant mouse MIP-1β (rmMIP-1β) elicited tactile allodynia. Moreover, rmMIP-1β increased the mRNA expression of inflammatory mediators in the SCN on day 1 after administration.
These results suggest that MIP-1β is a novel key mediator, and the peripheral MIP-1β-CCR5 axis contributes to neuropathic pain. Therefore, investigation of this cascade might be a validated approach for the elucidation of neuropathic pain mechanisms.
神经病理性疼痛是由神经损伤或功能障碍引起的,与神经病理性疼痛相关的症状对传统的镇痛药物有抗性。细胞因子-趋化因子网络引起的神经炎症可能在神经病理性疼痛中起关键作用。我们证明巨噬细胞炎性蛋白-1β(MIP-1β)参与神经病理性疼痛。
小鼠接受部分坐骨神经结扎(PSL),通过 von Frey 试验和 Hargreaves 试验分别评估触觉过敏和热痛觉过敏。将试剂施用于坐骨神经周围区域(SCN)。
使用逆转录聚合酶链反应,PSL 后损伤的 SCN 中 MIP-1β及其受体(CC-趋化因子受体 5;CCR5)的 mRNA 表达上调。MIP-1β免疫反应性定位于巨噬细胞和雪旺细胞中,并在损伤的 SCN 中于第 1 天增加。在第 0、3 和 6 天给予 MIP-1β中和抗体(抗-MIP-1β)可预防 PSL 引起的第 4 至 7 天的触觉过敏。用抗-MIP-1β治疗可抑制 PSL 诱导的损伤 SCN 中炎症细胞因子-趋化因子 mRNA 的上调,第 7 天。在第 0、3 和 6 天给予 CCR5 拮抗剂 D-ala-peptide T-amide(D-ala-peptide T-amide)可预防第 4 至 14 天的触觉过敏和热痛觉过敏。单次给予重组小鼠 MIP-1β(rmMIP-1β)可引起触觉过敏。此外,rmMIP-1β在给药后第 1 天增加了 SCN 中炎症介质的 mRNA 表达。
这些结果表明 MIP-1β是一种新型关键介质,外周 MIP-1β-CCR5 轴有助于神经病理性疼痛。因此,对该级联反应的研究可能是阐明神经病理性疼痛机制的有效方法。